Posters

Endophthalmitis: Cases review from a tertiary center in Lisbon between 2013 and 2019.

Poster Details

First Author: P.Vieira PORTUGAL

Co Author(s):    C. Xavier   D. Hipólito   L. Costa   F. Fernandes   R. Anjos        

Abstract Details

Purpose:

To review the cases of endophthalmitis admitted to our hospital between January 2013 and March 2019 and characterize the epidemiology, the time to diagnosis and treatment, the type of treatment and the outcomes.

Setting:

Lisbon Central University Hospital Center.

Methods:

Retrospective analysis of the endophthalmitis (n=59) admitted to our hospital between 2013 and 2019. We categorized the endophthalmitis according to the etiology. Several parameters were evaluated, namely, Manchester Triage System score, the time between the incident and the presentation, the time between admission and the first medical contact, the time between first medical contact and the intravitreal antibiotic injection, the visual acuity on presentation, the vitreous or aqueous biopsy, the treatment regimen, the repetition of intravitreal antibiotics, the timing of the repetition, the treatment with oral steroids, the vitrectomy, the timing of vitrectomy, the microbiological results and the visual outcome.

Results:

The mean time between admission and first medical contact was 53 minutes and the mean time between medical contact and intravitreal injection was 269 minutes (SD=197). 37% of the patients had a biopsy done at the time of treatment but only 26% of those biopsies was possible a microorganism isolation. In all cases an intravitreal injection of vancomycin and ceftazidime was performed, and only 33% had a second procedure. 29% received oral steroids and 40% were vitrectomized. Visual outcomes were poor, with only 17 patients (29%) maintaining a visual acuity >20/200.

Conclusions:

Endophthalmitis is a serious, potentially blinding condition, for which timely treatment can greatly impact the outcome. It is important to review the cohorts to implement protocols that assure the best possible care.

Financial Disclosure:

None